Brii Biosciences Limited (HKG:2137)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 830.08M -44.2% |
| Revenue (ttm) | 39.56M -28.8% |
| Net Income | -247.74M |
| EPS | -0.34 |
| Shares Out | 721.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,565,500 |
| Open | 1.130 |
| Previous Close | 1.130 |
| Day's Range | 1.100 - 1.180 |
| 52-Week Range | 1.100 - 2.540 |
| Beta | 1.26 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 28, 2026 |
About Brii Biosciences
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed ... [Read more]
Financial Performance
In 2025, Brii Biosciences's revenue was 35.55 million, a decrease of -28.81% compared to the previous year's 49.94 million. Losses were -222.62 million, -56.19% less than in 2024.
Financial numbers in CNY Financial StatementsNews
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
- Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone - Data from Cohort ...
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds
Brii Biosciences Earnings Call Transcript: H2 2025
Strong progress in HBV clinical programs and expanded discovery capabilities drove revenue growth, while disciplined cost control and a robust cash position support long-term development. Key HBV study results and new pipeline programs are expected later in 2026.
Brii Biosciences Earnings release: H2 2025
Brii Biosciences released its H2 2025 earnings on March 20, 2026, summarizing the period's financial results.
Brii Biosciences Annual report: H2 2025
Brii Biosciences has published its H2 2025 annual report on March 20, 2026.
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts Increasing Discovery Efforts to Drive Long-term Value Creation Strong Cash Position Supporting Strategic Priorities Upcoming Conference ...
Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine
Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional cure strategy DURHAM, N.C. and BEIJING , Nov. 7, 2025...
Brii Biosciences Earnings Call Transcript: H1 2025
Phase II-B HBV studies showed strong efficacy for BRII-179, with 61% antigen loss in responders. Cash reserves remain robust, supporting operations through 2028, while R&D and admin costs declined. Regulatory and market developments are expected to drive future growth.
Brii Biosciences Quarterly report: H1 2025
Brii Biosciences has published its H1 2025 quarterly earnings report on August 21, 2025.
Brii Biosciences Earnings release: H1 2025
Brii Biosciences released its H1 2025 earnings on August 21, 2025, summarizing the period's financial results.
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin Strong Cash Position ...
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threa...
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative tr...
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsA...
Brii Biosciences Annual report: H2 2024
Brii Biosciences has published its H2 2024 annual report on March 21, 2025.
Brii Biosciences Earnings release: H2 2024
Brii Biosciences released its H2 2024 earnings on March 21, 2025, summarizing the period's financial results.
Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study
Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply Several combination treatment studies containing BRII-179 have quickly started to ...
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA
48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Da...
Brii Biosciences Earnings Call Transcript: H1 2024
Advanced HBV cure candidates received breakthrough therapy designation in China, with strong clinical progress and significant cost reductions. Cash reserves are sufficient through 2027, and key phase II data readouts are expected in Q4 2024.
Brii Biosciences Quarterly report: H1 2024
Brii Biosciences has published its H1 2024 quarterly earnings report on August 20, 2024.
Brii Biosciences Earnings release: H1 2024
Brii Biosciences released its H1 2024 earnings on August 20, 2024, summarizing the period's financial results.
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection BRII-179 as add-on therapy in...
Brii Biosciences Earnings Call Transcript: H2 2023
Brii Biosciences Annual report: H2 2023
Brii Biosciences has published its H2 2023 annual report on March 25, 2024.
Brii Biosciences Earnings release: H2 2023
Brii Biosciences released its H2 2023 earnings on March 25, 2024, summarizing the period's financial results.